GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Debt-to-Asset

Sumitomo Pharma Co (Sumitomo Pharma Co) Debt-to-Asset : 0.39 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Sumitomo Pharma Co Debt-to-Asset?

Sumitomo Pharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,581 Mil. Sumitomo Pharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,280 Mil. Sumitomo Pharma Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $7,362 Mil. Sumitomo Pharma Co's debt to asset for the quarter that ended in Dec. 2023 was 0.39.

Sumitomo Pharma Co Debt-to-Asset Historical Data

The historical data trend for Sumitomo Pharma Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Debt-to-Asset Chart

Sumitomo Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.24 0.21 0.21 0.30

Sumitomo Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.30 0.33 0.33 0.39

Competitive Comparison of Sumitomo Pharma Co's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sumitomo Pharma Co's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Debt-to-Asset falls into.


Sumitomo Pharma Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sumitomo Pharma Co's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(677.728 + 1826.426) / 8489.492
=0.29

Sumitomo Pharma Co's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1580.675 + 1279.706) / 7361.849
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co  (OTCPK:DNPUF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sumitomo Pharma Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Debt-to-Asset
Comparable Companies
TSE:4540 TSE:4887 TSE:4547 TSE:4521 TSE:4534 TSE:4553 TSE:4569 TSE:4551 TSE:4559 TSE:4886 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 XSWX:SDZ VTRS NBIX
Traded in Other Exchanges
4506:Japan DPM:Germany
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Website
https://www.sumitomo-pharma.com
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.